Targeted compound daraxonrasib successfully blocks multiple KRAS variants to double survival limits in clinical trials.

Below are summaries of recent Fred Hutch Cancer Center research findings, patient stories and other news. If you’re interested in reporting on any of this month’s stories, contact media@fredhutch.org ...

Northwestern Medicine scientists have demonstrated that a highly sensitive blood test can detect traces of pancreatic cancer ...

SEATTLE — Pancreatic cancer is considered one of the deadliest cancers, with a five-year survival rate of just 13 percent, by ...

Pancreatic cancer is among the most aggressive types of cancer. Because symptoms appear very late, it’s often too late for successful cancer therapy. Early detection of this cancer type is therefore ...

Daraxonrasib was shown to have “landscape-changing” results in extending life expectancy, according to the American Society ...

Blocking IL1RAP, a receptor that sits at a key control point in inflammatory signaling, can disrupt the tumor-driven ...

A first-in-class nanoparticle injection sneaks antibodies into pancreatic cancer cells to clear mutant KRAS, shrinking tumors ...

The ultra-sensitive test can find hidden signs of pancreatic cancer by looking for a key KRAS genetic mutation missed by ...

Every year, more than 67,000 people are diagnosed with pancreatic cancer. In most cases, the disease has spread, and patients ...

Traditional therapeutics target the inactive conformation of proteins, allowing tumors to adapt and resume signaling.

A groundbreaking drug has nearly doubled survival rates for pancreatic cancer patients, offering new hope in the fight ...